Last reviewed · How we verify
Aselend — Competitive Intelligence Brief
discontinued
sodium selenite
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Aselend (SODIUM SELENITE) — Fujimoto Pharmaceutical Corporation. Aselend works by providing the body with selenium, an essential mineral that plays a crucial role in various bodily functions.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aselend TARGET | SODIUM SELENITE | Fujimoto Pharmaceutical Corporation | discontinued | sodium selenite |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (sodium selenite class)
- Fujimoto Pharmaceutical Corporation · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aselend CI watch — RSS
- Aselend CI watch — Atom
- Aselend CI watch — JSON
- Aselend alone — RSS
- Whole sodium selenite class — RSS
Cite this brief
Drug Landscape (2026). Aselend — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-selenite. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing